Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 02, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in interests in Ordinary shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share allocations rather than a financial performance report.
Material Changes
On October 1, 2007, Non-Executive Directors were provisionally allocated awards under share allocation arrangements for the service period of July 1, 2007, to September 30, 2007. The specific allocations are as follows:
- Sir Christopher Gent: 2,196.33 Ordinary Shares
- Dr Stephanie Burns: 341.37 ADSs
- Mr Lawrence Culp: 682.74 ADSs
- Sir Crispin Davis: 1,145.91 ADSs
- Sir Deryck Maughan: 682.74 ADSs
- Dr Daniel Podolsky: 469.38 ADSs
- Sir Ian Prosser: 859.43 ADSs
- Dr Ronaldo Schmitz: 458.37 ADSs
- Mr Tom de Swaan: 429.72 ADSs
- Sir Robert Wilson: 381.97 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding director share interests.
Investor Verification Points
- Confirm the final vesting status of the provisional share allocations listed for Non-Executive Directors.
- Verify the total number of Ordinary Shares and ADSs held by each director post-allocation to assess total exposure.
- Review the specific terms of the share allocation arrangements for the period of July 1, 2007, to September 30, 2007.